Cidara Therapeutics
San Diego, US · Founded 2012 · Delaware corporation · 44,945 employees on LinkedIn · 8 known investors
Find your way into Cidara Therapeutics
745 people in our graph share verified history with the Cidara Therapeutics team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Dirk Thye · together at Stanford University (overlapped)
×5knows the team · via University of California, Berkeley
×4knows the team · via Stanford University
knows the team · via UCLA
knows the team · via Theravance Biopharma
Pharmaceutical company developing medicines and vaccines for patient health and treatment. Operating for over 130 years with focus on clinical research and drug development.
Founders & leadership
Cidara Therapeutics was founded in 2012 by Jeffrey Stein and Kevin Judice.
JS
Jeffrey SteinCo-founder
KJ
Kevin JudiceinFounder, Cidara Therapeutics2012–2015Kevin Judice is CEO and co-founder of DICE Therapeutics. He has over 25 years of experience in biotech, including prior roles as founder and CEO of Achaogen, co-founder and Acting Chief Scientific Officer of Cidara Therapeutics, and an early employee at Theravance.
KF
Kevin ForrestExecutive
DT
KB
Ken BartizalinChief Development Officer2014–2018
PD
Paul DaruwalainChief Operating Officer2018–2022Paul Daruwala held COO and CCO roles at Cidara Therapeutics, where he led a Series B crossover financing and IPO, advanced the antifungal candidate rezafungin toward commercialization, and established clinical partnerships. Previously, he served as CEO of Cellics Therapeutics, advancing cell membrane coating nanotechnology for drug delivery, and held executive positions in business development and franchise leadership at Bristol Myers Squibb, Vertex Pharmaceuticals, and Merck & Co. across infectious disease and other therapeutic areas.
Board
SE
SR
Scott RocklageinBoard directorManaging Partner at 5AM Ventures with over 20 years of healthcare management experience
NK
PH
DB
Dan BurgessBoard director
TS
Ted SchroederBoard director
Investors · 8
5AM VenturesBoston · $100K – $4Mvia Scott Rocklage · board
Aisling CapitalNew York
Bain Capital Life SciencesBoston
Frazier Life SciencesPalo Altovia Patrick Heron · board
RA CapitalBoston
Vivo CapitalPalo Alto · $10M – $50M
Canaan PartnersreportedStamford · $500K – $20Mvia Nina Kjellson · board
Venrock Healthcare Capital PartnersreportedNew York
Reported raises · per SEC filings
Form D private placements$349.1M disclosed across 7 rounds · 2014–2024
▶$240MraisedMay 2024 · 7 investors · BiotechnologyRule 506(b)
▶$240MraisedMay 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carin Canale-TheakstonDirector
- Theodore R. SchroederDirector
- Daniel D. BurgessDirector
- Laura Tadvalkar, Ph.D.Director
- Taylor Sandison, M.D.Executive Officer
- Leslie Tari, Ph.D.Executive Officer
- Preetam Shah, Ph.D.Executive Officer
- Bonnie Bassler, Ph.D.Director
- James Merson, Ph.D.Director
- Ryan SpencerDirector
- Shane WardExecutive Officer
- Jeffrey Stein, Ph.D.Executive Officer, Director
- Offering amount
- $240M
- Amount sold
- $240M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9MraisedSep 2019 · 1 investors · BiotechnologyRule 506(b)
▶$9MraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey SteinExecutive Officer, Director
- Daniel D BurgessDirector
- Theodore R SchroederDirector
- David GollaherDirector
- Timothy FransonDirector
- Jessica OienExecutive Officer
- Taylor SandisonExecutive Officer
- Chrysa MineoDirector
- James LevineExecutive Officer
- Neil AbdollahianExecutive Officer
- Paul DaruwalaExecutive Officer
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedMay 2018 · 16 investors · BiotechnologyRule 506(b)
▶$1.6MraisedMay 2018 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Taylor SandisonExecutive Officer
- Robert J PerezDirector
- Theodore R SchroederDirector
- Matthew OnaitisExecutive Officer
- Jeffrey SteinExecutive Officer, Director
- Timothy R FransonDirector
- Daniel D BurgessDirector
- Scott M RocklageDirector
- Chrysa MineoDirector
- Offering amount
- $1.9M
- Amount sold
- $1.6M
- Sales commissions
- $1.9M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedOct 2017 · 16 investors · BiotechnologyRule 506(b)
▶$20.2MraisedOct 2017 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel D BurgessDirector
- Theodore R SchroederDirector
- Timothy R FransonDirector
- Kevin ForrestExecutive Officer
- Ken BartizalExecutive Officer
- Matthew OnaitisExecutive Officer
- Jeffrey SteinExecutive Officer, Director
- Taylor SandisonExecutive Officer
- Neil AbdollahianExecutive Officer
- Robert J PerezDirector
- Paul DaruwalaExecutive Officer
- Scott M RocklageDirector
- Offering amount
- $20.2M
- Amount sold
- $20.2M
- Finders' fees
- $1.1M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$42MraisedFeb 2015 · 19 investors · BiotechnologyRule 506(b)
▶$42MraisedFeb 2015 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey SteinExecutive Officer, Director
- Steve ElmsDirector
- Dan BurgessDirector
- Scott RocklageDirector
- Ted SchroederDirector
- Kevin ForrestExecutive Officer
- Dirk ThyeExecutive Officer
- Ken BartizalExecutive Officer
- Kevin JudiceDirector
- Paul DaruwalaExecutive Officer
- Nina KjellsonDirector
- Patrick HeronDirector
- Offering amount
- $42M
- Amount sold
- $42M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$30.3MraisedJun 2014 · 8 investors · BiotechnologyRule 506(b)
▶$30.3MraisedJun 2014 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey SteinExecutive Officer, Director
- Kevin ForrestExecutive Officer
- Nina KjellsonDirector
- Patrick HeronDirector
- Scott RocklageDirector
- Kevin JudiceExecutive Officer, Director
- Ted SchroederDirector
- Dan BurgessDirector
- Steve ElmsDirector
- Offering amount
- $42.7M
- Amount sold
- $30.3M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$6MraisedJun 2014 · 1 investors · BiotechnologyRule 506(b)
▶$6MraisedJun 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick HeronDirector
- Ted SchroederDirector
- Dan BurgessDirector
- Kevin ForrestExecutive Officer
- Nina KjellsonDirector
- Jeffrey SteinExecutive Officer, Director
- Steve ElmsDirector
- Kevin JudiceExecutive Officer, Director
- Scott RocklageDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Merck Stock Jumps on Phase 3 Cancer Vaccine Win as Keytruda Risk Easestradingkey.com · Aug 2026Frequently asked questions
- What does Cidara Therapeutics do?
- Pharmaceutical company developing medicines and vaccines for patient health and treatment. Operating for over 130 years with focus on clinical research and drug development.
- Who founded Cidara Therapeutics?
- Cidara Therapeutics was founded by Jeffrey Stein, Kevin Judice in 2012.
- Who are Cidara Therapeutics's investors?
- Cidara Therapeutics's investors include 5AM Ventures, Aisling Capital, Bain Capital Life Sciences, Frazier Life Sciences, RA Capital, Vivo Capital, Canaan Partners, Venrock Healthcare Capital Partners.
- How much funding has Cidara Therapeutics raised?
- Cidara Therapeutics has disclosed $349.1M raised across 7 rounds.
- Where is Cidara Therapeutics headquartered?
- Cidara Therapeutics is headquartered in San Diego, US.